Thus, an accurate assessment of liver fibrosis severity is important to guide treatment decisions and surveillance in patients living with Hepatitis B. Routine liver tests such as alanine aminotransferase (ALT) or HBV DNA levels are useful for disease activity and provide thresholds for treatment decisions but are inadequate for fibrosis severity. This evidence concerns the gene GPT and Hepatic fibrosis.